{"_id": "64ffe5a2748b29c10bbbeaf5", "nctId": "NCT04511013", "title": "A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases", "Not yet fixed MQL": "{\n\"and\": [\n{\n\"$and\": [\n{\"cancer type\": \"melanoma\"},\n{\"metastasized to the brain\": true}\n]\n},\n{\n\"$and\": [\n{\"primary origin\": {\"$in\": [\"cutaneous\", \"acral/mucosal\", \"unknown\"]}},\n{\"uveal primary\": {\"$ne\": true}}\n]\n},\n{\"BRAF-V600 mutant melanoma\": true},\n{\n\"$and\": [\n{\"MRI of the brain within 28 days prior to registration\": true},\n{\"central nervous system metastases with at least one measurable brain metastasis >= 0.5 cm in size\": true},\n{\"recommended MRI acquisition protocol\": true},\n{\"CT of the head cannot substitute for brain MRI\": true},\n{\"CNS disease documented on both Brain Metastases Baseline Tumor Assessment Form and Baseline Tumor Assessment Form\": true}\n]\n},\n{\n\"$and\": [\n{\"measurable or non-measurable extracranial disease\": true},\n{\"measurable disease assessed within 28 days prior to randomization\": true},\n{\"non-measurable disease assessed within 42 days prior to randomization\": true},\n{\"disease documented on Baseline Tumor Assessment Form\": true},\n{\"CNS disease documented on both Brain Metastases Baseline Tumor Assessment Form and Baseline Tumor Assessment Form\": true}\n]\n},\n{\"leptomeningeal disease\": true},\n{\"corticosteroids for brain metastases at a dose of up to 8 mg of dexamethasone per day for at least 7 days prior to randomization\": true},\n{\"Zubrod performance status =< 2\": true},\n{\"complete history and physical examination within 28 days prior to randomization\": true},\n{\"able to swallow and retain pills\": true},\n{\"hemoglobin >= 8.0 g/dL within 28 days prior to randomization\": true},\n{\"absolute neutrophil count >= 1,500/mcL within 28 days prior to randomization\": true},\n{\"platelets >= 75,000/mcL within 28 days prior to randomization\": true},\n{\"total bilirubin =< 1.5 institutional upper limit of normal (ULN) within 28 days prior to randomization\": true},\n{\"AST and ALT =< 2.5 x institutional ULN (in participants with liver metastases =< 5 x ULN) within 28 days prior to randomization\": true},\n{\"creatinine =< 2.0 institutional ULN within 28 days prior to randomization\": true},\n{\n\"$and\": [\n{\"known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents\": true},\n{\"clinical risk assessment of cardiac function using the New York Heart Association Functional Classification\": true},\n{\"NYHA class =< 2B\": true}\n]\n},\n{\n\"$and\": [\n{\"prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen\": true},\n{\"eligible for this trial\": true}\n]\n},\n{\n\"$and\": [\n{\"known human immunodeficiency virus (HIV)-infection\": true},\n{\"on effective anti-retroviral therapy and undetectable viral load at their most recent viral load test and within 90 days prior to randomization\": true}\n]\n},\n{\n\"$and\": [\n{\"known history of hepatitis C virus (HCV) infection\": true},\n{\"treated and cured\": true},\n{\"undetectable HCV viral load prior to randomization\": true}\n]\n},\n{\"image banking participation\": true},\n{\"offered opportunity to participate in specimen and blood collections\": true},\n{\"informed of the investigational nature of this study and signed informed consent\": true},\n{\"institutional review board approval within 365 days\": true}\n]\n},\n{\n\"$not\": {\n\"$or\": [\n{\"prior systemic therapy for metastatic disease\": true},\n{\"prior radiation therapy within 7 days prior to randomization\": true},\n{\"additional form of systemic anti-tumor therapy for melanoma while on protocol treatment\": true},\n{\"use of hormonal contraceptives\": true},\n{\"serious active infection requiring systemic therapy at time of randomization\": true},\n{\"active autoimmune disease requiring treatment in the past 6 months with biologic disease modifying agents\": true},\n{\"grade 3 or 4 immune-related adverse events on ipilimumab or nivolumab requiring more than 12 weeks of immune suppression with corticosteroids\": true},\n{\"adverse events related to encorafenib and/or binimetinib requiring discontinuation of one or both drugs\": true},\n{\"pregnant or nursing\": true},\n{\"known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, clinical risk assessment of cardiac function using the New York Heart Association Functional Classification, NYHA class =< 2B\": true},\n{\"prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen\": true},\n{\"known human immunodeficiency virus (HIV)-infection on effective anti-retroviral therapy and undetectable viral load at their most recent viral load test and within 90 days prior to randomization\": true},\n{\"known history of hepatitis C virus (HCV) infection treated and cured, undetectable HCV viral load prior to randomization\": true}\n]\n}\n}\n]\n}"}